Ganga Pharmaceuticals opened lower at -, compared with its previous close of ₹12.50. During today's session, the stock has traded between - and -, with an average traded price of -. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Ganga Pharmaceuticals is now worth
₹ 25,000.00
Giving a profit of
₹ 15,000.00 (150.00%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.00 (+0.00%)
Day High
-
Day Low
-
Day Open
-
Prev Close
₹12.50
Volume
-
Value Traded
-
1W Return
0.00%
1M Return
0.00%
3M Return
0.00%
6M Return
0.00%
1Y Return
-17.81%
Market Cap (₹ Cr.)
7
PE Ratio
73.50
PB Ratio
0.89
Dividend Yield
-
ROE
1.22%
ROCE
3.12%
Book Value (₹)
14.06
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.00%
6 Weeks
-
1 Month
0.00%
3 Months
0.00%
9 Months
4.17%
No data available.
Ganga Pharmaceuticals Q2FY27 Results: Net profit down 66% YoY to ₹1.86 lakh
Net profit declined 66.2% YoY to ₹1.86 lakh in H1FY27. Revenue from operations rose 3.6% YoY to ₹141.63 lakh. Cost of materials consumed increased to ₹80.42 lakh from ₹70.04 lakh. Cash and cash equivalents decreased to ₹2.17 lakh from ₹5.82 lakh.
10 days agoGanga Pharmaceuticals re-appoints Bharat Sharma as MD for 3 years
Members approved Bharat Brijmohan Sharma's re-appointment as Managing Director. New term lasts three years effective April 1, 2026. Sharma has over 35 years of experience in the pharma industry. He is not liable to retire by rotation during this tenure.
1mo agoGanga Pharmaceuticals AGM sees 100% approval for all resolutions
All three AGM resolutions passed with 100% votes in favor. Promoters cast 3,009,550 votes; Public non-institutions cast 192,110 votes. Zero votes were cast against any resolution during the meeting. Meeting held on September 26, 2026, with quorum met by 10 members.
1mo agoGanga Pharmaceuticals schedules AGM for Sept 26; proposes MD reappointment
Ganga Pharmaceuticals schedules its 37th AGM for September 26, 2026. Shareholders to approve FY26 results showing PAT rise to ₹10.15 crore. Special resolution seeks reappointment of MD Bharat Sharma for three years. E-voting window opens on September 23 and closes on September 25. Company ensures physical notice access for unregistered shareholders.
2mo agoGanga Pharmaceuticals appoints auditor for FY 2026-27
Ganga Pharmaceuticals Limited has appointed M/s. D Maurya & Associates as its Secretarial Auditor for FY 2026-27 following a Board meeting on May 21, 2026. The firm, led by Mr. Dhirendra Maurya, brings expertise in SEBI LODR compliance and company law advisory.
5mo agoGanga Pharmaceuticals Appoints Deepak Jedhe & Co as Internal Auditor
Ganga Pharmaceuticals Limited has appointed M/s. Deepak Jedhe & Co as its Internal Auditor for FY 2026-27 following a Board meeting on May 21, 2026. The firm, founded in 2015, specializes in Assurance, Taxation, and Advisory services. The appointment was based on the Audit Committee's recommendation.
5mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,899.30 | +0.76% | ₹4,55,705.69 | 41.20 | +9.65% | |
| ₹11,495.00 | +0.09% | ₹3,05,156.13 | 90.40 | +76.30% | |
| ₹4,685.20 | -0.89% | ₹1,78,209.95 | 85.50 | +22.50% | |
| ₹2,427.00 | +1.13% | ₹1,31,133.78 | 97.10 | +145.34% | |
| ₹1,204.50 | -0.12% | ₹1,20,149.34 | 28.00 | +26.60% | |
| ₹1,388.30 | +0.12% | ₹1,15,878.66 | 42.00 | +12.91% | |
| ₹1,409.80 | +0.11% | ₹1,13,891.88 | 39.90 | -7.21% | |
| ₹2,663.30 | +0.94% | ₹1,10,006.30 | 48.10 | +17.33% | |
| ₹1,808.90 | +0.09% | ₹1,04,080.11 | 26.00 | +52.83% | |
| ₹2,019.10 | +0.20% | ₹92,331.42 | 17.60 | -0.73% | |
| ₹2,639.00 | -0.78% | ₹74,479.09 | 51.60 | +42.82% | |
| ₹5,194.00 | -2.04% | ₹62,102.06 | 30.50 | -9.94% |
An investment of ₹10,000 made 5 years ago in Ganga Pharmaceuticals is now worth
₹ 25,000.00
Giving a profit of
₹ 15,000.00 (150.00%)
Note: Past profits do not guarantee future returns.
